What is HEPA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for HEPA?

P/E (TTM) is n/a and 52-week range is $0.03 to $0.22 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s HEPA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for HEPA?

The company profile lists net income (TTM) near -$533M, EPS (TTM) near -$48.55 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Hepion Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Edison, New Jersey, US, 11M shares outstanding, ISIN US4268974015 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Hepion Pharmaceuticals Inc

$HEPA

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. The company is headquartered in Edison, New Jersey. The company went IPO on 2014-02-07. Through its subsidiary Gravitas Life Sciences, LLC, a clinical-stage biotechnology company, it is advancing therapeutic candidates in immunology and inflammation, including a transmucosal buccal film of an established opioid antagonist and an oral formulation of a validated anti-inflammatory antibody. Its diagnostic program is built on circulating tumor RNA technology, which reads actively expressed tumor transcripts for the early detection of hepatocellular carcinoma in high-risk cirrhotic patients, a cancer that is curable when found early. Its two licensed programs include GV104 and GV023. GV104 is a transmucosal buccal film of an approved opioid antagonist in clinical development for the temporary prophylaxis of respiratory and/or central nervous system depression. GV023 is an oral formulation of infliximab.

Employees

Website

hepionpharma.com/

IPO

2014-02-07

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US4268974015

Headquarters

Edison, New Jersey, US

Shares outstanding

11M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

0.00%

Browse other companiesFree AI scores and summaries for more stocks